Several targeting approaches are in development. BCMA is preferentially expressed on plasma cells and other mature B cells in blood 5. These cells originate with B-lymphocyte progenitors that ...

为探究 BCMA 靶向疗法治疗多发性骨髓瘤（MM）的效果，研究人员总结 2024 ASH 年会成果，为患者带来希望。 在血液疾病的领域中，多发性骨髓瘤（Multiple Myeloma，MM）一直是困扰医学界的难题。这是一种恶性浆细胞病，随着病情发展，患者的正常造血功能受到抑制 ...

With the undeniable excitement in the BCMA field over the past few months, the BCMA Targeted Therapies Summit returns to the space to equip you with the knowledge and connections to revolutionize ...

Blenrep (belantamab mafodotin) becomes the first BCMA-targeted drug for myeloma to be approved in the EU, and according to its label can be used to treat the blood cancer in adult patients who ...